PBHC Pathfinder Bancorp, Inc. Insider Trading

General Counsel Polniak buys 1,000 shares of PBHC at $15.88; holdings rise to 9,000 shares

Joseph Polniak, FVP and General Counsel, purchased 1,000 shares at $15.88 on 2026-06-15, increasing his holdings from 8,000 to 9,000 shares. The transaction occurred near the 52-week high of $16.88, with the stock currently priced at $15.61 following a +15.7% gain over the past 30 days and +18.4% gain over 90 days. Notable context: the company reported negative full-year net income despite showing current-period net income of $2,413,000.00, creating a mixed financial picture that makes this insider acquisition a data point rather than a clear signal of management conviction.

PBHC CEO James A. Dowd bought 1,400 shares at $13.68; prior trades at ticker both showed +90d gains

CEO James A. Dowd purchased 1,400 shares at $13.68 on 2026-06-02, increasing his holdings from 18,052 shares to 19,452 shares. His two prior open-market purchases at PBHC both generated positive 90-day returns (Buy on 2024-03-13: 90d +1.2%; Buy on 2024-03-12: 90d +6.9%), establishing a pattern of well-timed entry points at this ticker. Cross-ticker, his track record shows 2 prior buys with an average 90-day return of +4.1% and a 100.00% win rate. The company faces fundamental headwinds, having been unprofitable over its most recent full fiscal year, though current net income stands at $2,413,000.00, with a P/E of 12.05 and market cap of $64,209,792.60. This purchase occurs while the stock trades 11.6% below its 52-week high of $15.96, presenting a factual observation of the trade's placement relative to recent price history.

Director Gagas Adam C. bought 1,956 shares at blended $13.75; stock down 22.1% from 52-week high

Gagas Adam C. completed two separate purchases totaling 1,956 shares for $26,893.50, increasing his holdings from 15,800 shares to 17,756 shares (a 12.4% increase). The purchases occurred at $13.50 and $13.75, prices below the current market price of $13.60 is slightly below the second transaction price, and significantly below the 52-week high of $17.45. The stock has declined 22.1% from its 52-week high and 4.4% over the past 30 days, placing this purchase activity in a period of price weakness. At a P/E of 8.19 and market cap of $61.9M, the company trades at relatively modest valuation multiples, though these metrics alone do not determine the rationale for the insider's purchase timing.

Director Ayoub David A. bought 425 shares of PBHC at $12.83; stock now -25.7% from 52-week high at $12.97

Director Ayoub David A. purchased 425 shares of Pathfinder Bancorp at $12.83, expanding his holdings to 19,188 shares (+2.3%). The stock is currently trading at $12.97, down significantly from its 52-week high of $17.45 and down 9.0% over the past month. Examining his same-ticker history at PBHC, his 2 prior buys showed mixed results: one delivered a 20.9% 90-day return while the other returned -2.1%, indicating inconsistent timing at this specific ticker. With the company trading at a P/E of 7.81 on a $59.1M market cap, the transaction reflects continued director participation, though the stock's recent weakness and modest transaction size ($5,452.75) merit observation rather than strong conviction signals.

Director Ayoub David A. purchased 1,000 shares of PBHC at $14.95 on 2025-05-05; stock down -22.3% from 52-week high.

Director Ayoub David A. purchased 1,000 shares at $14.95, bringing his holdings to 18,763 shares. The stock is trading at $14.70, down 10.1% over 30 days and 14.9% over 90 days, and currently trades 22.3% below its 52-week high of $18.91. Notably, the company reported net income of -$4,644,000.00, indicating negative earnings. While his cross-ticker track record shows 1 prior buy with a 90-day return of +20.9%, his only prior PBHC purchase on 2024-05-07 yielded a 90-day return of +20.9%, suggesting a pattern of well-timed entry points at this company. The current buy occurs in a period of price decline and negative profitability, warranting examination of whether this represents conviction at depressed levels or routine portfolio activity.